Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2021

Feb 17, 2021

33148_dirs_2021-02-16_5335f182-4faf-453a-94f0-db66a7bbef1f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2020-12-31

Reporting Person: GRANADILLO PEDRO P (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-12-28 Stock Option (Right to Buy) $14.56 G 30000 Disposed 2029-01-28 Common Stock (30000) Direct
2020-12-28 Stock Option (Right to Buy) $14.56 G 30000 Acquired 2029-01-28 Common Stock (30000) Indirect
2020-12-28 Stock Option (Right to Buy) $18.75 G 40000 Disposed 2028-03-29 Common Stock (40000) Direct
2020-12-28 Stock Option (Right to Buy) $18.75 G 40000 Acquired 2028-03-29 Common Stock (40000) Indirect
2020-12-28 Stock Option (Right to Buy) $19.9 G 20000 Disposed 2030-06-16 Common Stock (20000) Direct
2020-12-28 Stock Option (Right to Buy) $19.9 G 20000 Acquired 2030-06-16 Common Stock (20000) Indirect

Footnotes

F1: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which are currently vested and exercisable.

F2: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 37,778 of which are currently vested and exercisable, with the remaining 2,222 shares vesting in equal monthly installments on each of February 28, 2021 and March 29, 2021.

F3: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021.